68 related articles for article (PubMed ID: 15593349)
1. Multiparametric characterization by flow cytometry of flow-sorted subpopulations of a human hepatoma cell line useful for drug research.
O'Connor JE; Martínez A; Castell JV; Gómez-Lechón MJ
Cytometry A; 2005; 63(1):48-58. PubMed ID: 15593349
[TBL] [Abstract][Full Text] [Related]
2. HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro.
Lübberstedt M; Müller-Vieira U; Mayer M; Biemel KM; Knöspel F; Knobeloch D; Nüssler AK; Gerlach JC; Zeilinger K
J Pharmacol Toxicol Methods; 2011; 63(1):59-68. PubMed ID: 20460162
[TBL] [Abstract][Full Text] [Related]
3. HepaRG cells as human-relevant in vitro model to study the effects of inflammatory stimuli on cytochrome P450 isoenzymes.
Rubin K; Janefeldt A; Andersson L; Berke Z; Grime K; Andersson TB
Drug Metab Dispos; 2015 Jan; 43(1):119-25. PubMed ID: 25371393
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of phase I and II enzyme activities in 5 hepatic cell lines identifies Huh-7 and HCC-T cells with the highest potential to study drug metabolism.
Lin J; Schyschka L; Mühl-Benninghaus R; Neumann J; Hao L; Nussler N; Dooley S; Liu L; Stöckle U; Nussler AK; Ehnert S
Arch Toxicol; 2012 Jan; 86(1):87-95. PubMed ID: 21735230
[TBL] [Abstract][Full Text] [Related]
5. Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines.
Brandon EF; Bosch TM; Deenen MJ; Levink R; van der Wal E; van Meerveld JB; Bijl M; Beijnen JH; Schellens JH; Meijerman I
Toxicol Appl Pharmacol; 2006 Feb; 211(1):1-10. PubMed ID: 15975613
[TBL] [Abstract][Full Text] [Related]
6. Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein.
von Moltke LL; Weemhoff JL; Perloff MD; Hesse LM; Harmatz JS; Roth-Schechter BF; Greenblatt DJ
Biopharm Drug Dispos; 2002 Dec; 23(9):361-7. PubMed ID: 12469329
[TBL] [Abstract][Full Text] [Related]
7. Hepatic cell lines for drug hepatotoxicity testing: limitations and strategies to upgrade their metabolic competence by gene engineering.
Donato MT; Jover R; Gómez-Lechón MJ
Curr Drug Metab; 2013 Nov; 14(9):946-68. PubMed ID: 24160292
[TBL] [Abstract][Full Text] [Related]
8. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.
Parkinson A; Mudra DR; Johnson C; Dwyer A; Carroll KM
Toxicol Appl Pharmacol; 2004 Sep; 199(3):193-209. PubMed ID: 15364537
[TBL] [Abstract][Full Text] [Related]
9. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.
Guillouzo A; Corlu A; Aninat C; Glaise D; Morel F; Guguen-Guillouzo C
Chem Biol Interact; 2007 May; 168(1):66-73. PubMed ID: 17241619
[TBL] [Abstract][Full Text] [Related]
10. Expression and induction of a large set of drug-metabolizing enzymes by the highly differentiated human hepatoma cell line BC2.
Gómez-Lechón MJ; Donato T; Jover R; Rodriguez C; Ponsoda X; Glaise D; Castell JV; Guguen-Guillouzo C
Eur J Biochem; 2001 Mar; 268(5):1448-59. PubMed ID: 11231298
[TBL] [Abstract][Full Text] [Related]
11. Size-dependent effects of nanoparticles on the activity of cytochrome P450 isoenzymes.
Fröhlich E; Kueznik T; Samberger C; Roblegg E; Wrighton C; Pieber TR
Toxicol Appl Pharmacol; 2010 Feb; 242(3):326-32. PubMed ID: 19909766
[TBL] [Abstract][Full Text] [Related]
12. An in vitro tool to assess cytochrome P450 drug biotransformation-dependent cytotoxicity in engineered HepG2 cells generated by using adenoviral vectors.
Lahoz A; Vilà MR; Fabre M; Miquel JM; Rivas M; Maines J; Castell JV; Gómez-Lechón MJ
Toxicol In Vitro; 2013 Jun; 27(4):1410-5. PubMed ID: 22910125
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and metabolism of a cysteinyl leukotriene-1 receptor antagonist from the heterocyclic chromanol series in rats: in vitro-in vivo correlation, gender-related differences, isoform identification, and comparison with metabolism in human hepatic tissue.
Kuperman AV; Kalgutkar AS; Marfat A; Chambers RJ; Liston TE
Drug Metab Dispos; 2001 Nov; 29(11):1403-9. PubMed ID: 11602515
[TBL] [Abstract][Full Text] [Related]
14. Oltipraz-mediated changes in aflatoxin B(1) biotransformation in rat liver: implications for human chemointervention.
Buetler TM; Bammler TK; Hayes JD; Eaton DL
Cancer Res; 1996 May; 56(10):2306-13. PubMed ID: 8625305
[TBL] [Abstract][Full Text] [Related]
15. Increased hepatic functionality of the human hepatoma cell line HepaRG cultured in the AMC bioreactor.
Nibourg GA; Hoekstra R; van der Hoeven TV; Ackermans MT; Hakvoort TB; van Gulik TM; Chamuleau RA
Int J Biochem Cell Biol; 2013 Aug; 45(8):1860-8. PubMed ID: 23770120
[TBL] [Abstract][Full Text] [Related]
16. HepG2 cells: an in vitro model for P450-dependent metabolism of acetaminophen.
Roe AL; Snawder JE; Benson RW; Roberts DW; Casciano DA
Biochem Biophys Res Commun; 1993 Jan; 190(1):15-9. PubMed ID: 8380689
[TBL] [Abstract][Full Text] [Related]
17. Primary porcine enterocyte and hepatocyte cultures to study drug oxidation reactions.
Bader A; Hansen T; Kirchner G; Allmeling C; Haverich A; Borlak JT
Br J Pharmacol; 2000 Jan; 129(2):331-42. PubMed ID: 10694240
[TBL] [Abstract][Full Text] [Related]
18. [New perspectives in the use of human hepatocytes in the preclinical drug development process].
Guillouzo A
Ann Pharm Fr; 2008; 66(5-6):288-95. PubMed ID: 19061728
[TBL] [Abstract][Full Text] [Related]
19. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties.
Wilkening S; Stahl F; Bader A
Drug Metab Dispos; 2003 Aug; 31(8):1035-42. PubMed ID: 12867492
[TBL] [Abstract][Full Text] [Related]
20. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells.
Aninat C; Piton A; Glaise D; Le Charpentier T; Langouët S; Morel F; Guguen-Guillouzo C; Guillouzo A
Drug Metab Dispos; 2006 Jan; 34(1):75-83. PubMed ID: 16204462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
